CIBC Private Wealth Group
INO icon

CIBC Private Wealth Group’s Inovio Pharmaceuticals INO Stock Holding History

CIBC Private Wealth Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$87K Buy
50,000
+49,986
+357,043% +$110K ﹤0.01% 1582
2025
Q3 		$33 Sell
14
-79,986
-100% -$153K ﹤0.01% 3021
2025
Q2 		$163K Buy
80,000
+40,000
+100% +$76.7K ﹤0.01% 1199
2025
Q1 		$58.4K Buy
+40,000
New +$80.3K ﹤0.01% 1580
2024
Q3 		– Sell
-358
Closed -$3.11K – 3199
2024
Q2 		$3.11K Sell
358
-10,000
-97% -$105K ﹤0.01% 2666
2024
Q1 		$136K Buy
+10,358
New +$89.4K ﹤0.01% 1268
2023
Q3 		– Sell
-9,926
Closed -$53.2K – 1106
2023
Q2 		$53.2K Buy
9,926
+7,167
+260% +$57.8K ﹤0.01% 858
2023
Q1 		$27.1K Hold
2,759
– – ﹤0.01% 875
2022
Q4 		$52 Hold
2,759
– – ﹤0.01% 839
2022
Q3 		$57K Buy
+2,759
New +$70.6K ﹤0.01% 886
2019
Q1 		– Sell
-5,375
Closed -$258K – 941
2018
Q4 		$258K Buy
+5,375
New +$327K ﹤0.01% 794

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIBC Private Wealth Group's INO Position: Q4 2025 in Review

CIBC Private Wealth Group increased its Inovio Pharmaceuticals (INO) stake by 357,043% in Q4 2025, buying an estimated $110K and bringing the position to 50,000 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #1582.

CIBC Private Wealth Group first reported a position in INO in Q4 2018 and has held it in 11 quarters since. The position peaked at $258K in Q4 2018. 102 funds tracked by Wall St. Rank hold INO as of Q4 2025.

  • CIBC Private Wealth Group held 50,000 shares of Inovio Pharmaceuticals worth $87K as of Q4 2025.
  • CIBC Private Wealth Group bought 49,986 Inovio Pharmaceuticals shares in Q4 2025, an estimated $110K.
  • Inovio Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #1582 holding.
  • CIBC Private Wealth Group first reported a position in Inovio Pharmaceuticals in Q4 2018 and has held it in 11 quarters since.
  • CIBC Private Wealth Group's Inovio Pharmaceuticals position peaked at $258K in Q4 2018.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.